Female Sexual Dysfunction Treatment Market - By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy), Disease (Dyspareunia, HSDD), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Global Forecast (2024

Description

Global Female Sexual Dysfunction Treatment Market will witness 10% CAGR from 2024 to 2032, fueled by advancements in therapeutics targeting various aspects of female sexual dysfunction, coupled with increasing awareness and destigmatization of sexual health issues.

As new treatments for conditions like hypoactive sexual desire disorder HSDD are gaining approval as well as acceptance and educational efforts are expanding, more women are seeking effective solutions. This trend is fostering a growing demand for personalized and effective therapies for enhancing access to comprehensive care and contributing to the evolution towards addressing diverse sexual health needs globally. For instance, in December 2023, Sha Wellness Clinic introduced a Sexual Health Unit as part of its Preventive and Healthy Ageing Medicine program for focusing on comprehensive wellness.

The female sexual dysfunction treatment industry is classified based on drug, disease, route of administration, distribution channel, and region.

By drug, the ospemifene segment will witness robust growth through 2032 due to its effectiveness in addressing symptoms like vaginal dryness and dyspareunia in menopausal women. With its approval for use in hormone receptor-positive breast cancer patients and non-estrogenic mechanism of action, ospemifene offers a viable therapeutic option. As healthcare providers seek safe and effective treatments for sexual health issues, ospemifene will render efficacy and safety, making it a leading choice in the evolving landscape of female sexual dysfunction treatments.

In terms of disease, the HSDD segment will observe a noteworthy CAGR between 2024 and 2032. As the most common form of female sexual dysfunction, HSDD affects libido and intimacy. With increasing awareness and advancements in treatment options like flibanserin, approved specifically for HSDD, there is a growing focus on addressing this prevalent issue. The strong emphasis of healthcare providers on improving sexual wellness and quality of life will favor the segment growth.

Asia Pacific female sexual dysfunction treatment market will hold significant share by 2032, attributed to increasing healthcare awareness and the rising demand for personalized therapies. With expanding healthcare infrastructure and research initiatives, the diverse population of the region is contributing significantly to advancing treatment options. With governments prioritizing women health and the evolving regulatory frameworks, Asia Pacific will stand out as a central contributor to shaping the industry growth.

Product Code: 9138

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Increasing awareness regarding female sexual health issues
- 3.2.3 Growing focus towards women's health
- 3.2.4 Rising research & development activities
- 3.2.5 Increasing advancements in medical technology
- 3.2.6 Industry pitfalls & challenges
- 3.2.7 Societal stigma and taboos associated with female sexual health
- 3.2.8 High treatment costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Flibanserin
5.3 Bremelanotide
5.4 Ospemifene
5.5 Estrogen therapy
5.6 Other drugs

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dyspareunia
6.3 Hypoactive sexual desire disorder (HSDD)
6.4 Other diseases

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Apricus Biosciences, Inc.
10.2 Cipla Limited
10.3 Freya Pharma Solutions
10.4 GSK plc
10.5 Lawley Pharmaceuticals Pty Ltd.
10.6 Merck & Co., Inc.
10.7 Millicent Pharma Limited
10.8 Novo Nordisk
10.9 Pfizer, Inc.
10.10 Sprout Pharmaceuticals, Inc

Female Sexual Dysfunction Treatment Market - By Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy), Disease (Dyspareunia, HSDD), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Global Forecast (2024 - 2032)